PT - JOURNAL ARTICLE AU - Jessica A. Scaborough AU - Martin C. Tom AU - Jacob G. Scott TI - Revisiting a null hypothesis: exploring the parameters of oligometastasis treatment AID - 10.1101/2020.08.10.20172098 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.10.20172098 4099 - http://medrxiv.org/content/early/2020/08/11/2020.08.10.20172098.short 4100 - http://medrxiv.org/content/early/2020/08/11/2020.08.10.20172098.full AB - In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis: patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. In this work, we suggest shifting this qualitative null hypothesis, and describe a mathematical model which can be used to frame a new, quantitative null. We begin with a very simple formulation of tumor growth, an exponential function, and use it to show that while any amount of cell kill will extend survival, in many cases the extent is so small as to be unnoticeable in a clinical context or out-weighed by factors related to toxicity and treatment time. Recasting the null in these quantitative terms will allow trialists to design trials specifically to increase understanding of what circumstances (patient selection, disease burden, tumor growth kinetics) can lead to improved OS when targeting metastatic lesions, rather than whether or not targeting metastases extends survival for patients with (oligo-)metastatic disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJGS thanks the NIH for their support through NIH R37CA244613 and their generous Loan Repayment Program and the American Cancer Society for the Research Scholar Grant (Award number: 132691-RSG-20-096-01-CSM). JAS was supported in part by NIH grant T32 GM007250.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There was no IRB approval necessary for this study as it does not utilize or generate new clinical data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used in this manuscript may be found at in the link provided. https://github.com/jessicascarborough/oligo-null